Biodistribution, pharmacokinetics, and organ-level dosimetry for ¹⁸⁸Re-AHDD-Lipiodol radioembolization based on quantitative post-treatment SPECT/CT scans.

ABSTRACT:

Background

Rhenium-188-labelled-Lipiodol radioembolization is a safe and cost-effective treatment for primary liver cancer. In order to determine correlations between treatment doses and patient response to therapy, accurate patient-specific dosimetry is required. Up to date, the reported dosimetry of ¹⁸⁸Re-Lipiodol has been based on whole-body (WB) planar imaging only, which has limited quantitative accuracy. The aim of the present study is to determine the in vivo pharmacokinetics, bio-distribution, and organ-level dosimetry of ¹⁸⁸Re-AHDD-Lipiodol radioembolization using a combination of post-treatment planar and quantitative SPECT/CT images. Furthermore, based on the analysis of the pharmacokinetic data, a practical and relatively simple imaging and dosimet

SUBMITTER: Esquinas PL 

PROVIDER: S-EPMC6283804 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature